Herein we further show that the applicability of this technology allows for enhanced reactivity of TIL towards autologous FRα expressing tumor types (lung, renal and ovarian) tumor both in vitro and in vivo and as such sets the scene for FRα CoStAR being evaluated clinically in a phase 1 trial. This evidence concerns the gene FOLR1 and neoplasm.